Health Economics›Osteosarcoma›Adjuvant therapy

Adjuvant therapy

Osteosarcoma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
IP-BCD Variant #01 Partial	—	R 34 695	35d	—	—	~3	~R 104 086 indirect	—
MAPIE Variant #01 Partial	—	R 33 666	69d	—	—	~7	~R 117 440 indirect	—
MAPI Variant #01	—	R 33 663	42d	—	—	~3	~R 100 988 indirect	—
M-EI Variant #02	—	R 27 221	28d	—	—	~7	~R 57 485 indirect	—
IE Variant #01	—	R 22 128	21d	—	—	~12	~R 265 533 indirect	—
Cisplatin, Epirubicin, Ifosfamide Variant #01	—	R 16 130	21d	—	—	~3	~R 48 389 indirect	—
MA-BCD/AP Variant #01 Partial	—	R 14 403	7d	—	—	~11	~R 65 441 indirect	—
M-BCD Variant #01 Partial	—	R 12 902	35d	—	—	~2	~R 25 803 indirect	—
MAP Variant #01	—	R 11 696	21d	—	—	~4	~R 27 070 indirect	—
Methotrexate and Vincristine Variant #01	—	R 4 191	14d	—	—	~2	~R 4 720 indirect	—
Cisplatin and Doxorubicin Variant #01	—	R 1 434	21d	—	—	4	R 5 734 PFS proxy	1
MA Variant #01	—	R 1 341	28d	—	—	~7	~R 5 725 indirect	—
Doxorubicin monotherapy Variant #01	—	R 902	21d	~5.8 mo	~19.0 mo	~9	~R 8 114 PFS proxy · indirect	7
Observation Partial	—	—	—	—	~97.6 mo	—	—	3

14 of 14 regimens shown